In vivo最新文献

{"title":"Survival Predictors in Obstructive Colorectal Cancer: A Combined Clinical, Inflammatory, and Histopathological Approach.","authors":"Ahmet Tarik Harmantepe, Adem Şentürk","doi":"10.21873/invivo.14041","DOIUrl":"10.21873/invivo.14041","url":null,"abstract":"<p><strong>Background/aim: </strong>Obstructive colorectal cancer (oCRC) accounts for a significant proportion of colorectal malignancies and is associated with poor prognosis and higher perioperative morbidity. Inflammation-based biomarkers have emerged as potential predictors of survival in various cancers. However, their prognostic role in oCRC remains unclear.</p><p><strong>Patients and methods: </strong>This retrospective study included patients who underwent surgery for histopathologically confirmed oCRC at Sakarya University Training and Research Hospital between January 2015 and February 2024. Preoperative systemic inflammatory markers-C-reactive protein-to-albumin ratio (CAR), lymphocyte-to-C-reactive protein ratio (LCR), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory index (SII), and HALP score-were analyzed. Overall survival was recorded, and statistical analyses were performed.</p><p><strong>Results: </strong>Among the inflammatory markers, CAR, LCR, and PNI were significantly associated with overall survival at 1, 3, and 5 years (<i>p</i> <0.05). LCR demonstrated the highest sensitivity and specificity in predicting mortality. Patients with higher CAR and lower PNI values had significantly poorer outcomes.</p><p><strong>Conclusion: </strong>Preoperative systemic inflammatory markers, particularly LCR, CAR, and PNI, are valuable prognostic indicators in patients with oCRC. These easily obtainable markers may help guide clinical decision-making and improve individualized patient management.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2419-2428"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors.","authors":"Manabu Watanabe, Hiroyuki Tsuchie, Hiroyuki Nagasawa, Michio Hongo, Yuji Kasukawa, Daisuke Kudo, Fumihito Kasama, Keita Oya, Takashi Kawaragi, Naohisa Miyakoshi","doi":"10.21873/invivo.13995","DOIUrl":"10.21873/invivo.13995","url":null,"abstract":"<p><strong>Background/aim: </strong>Breast cancer frequently metastasizes to the bone, reducing quality of life and survival. Zoledronic acid (ZA), is used to treat bone metastasis; however, differences in efficacy depending on the timing of administration are not clear. This study investigated the effects of different timing of ZA administration in a mouse model of breast cancer bone metastasis.</p><p><strong>Materials and methods: </strong>E0771 cells (1.0×10⁵ cells/10 μl) were injected into the femur of C57BL/6 mice to create a local bone metastasis model. The groups that started ZA administration one week before, at the same time as, one week after, and two weeks after tumor-cell administration were designated as the -1w, 0w, 1w, and 2w groups, respectively. A fifth group that did not receive ZA treatment was created as a control. ZA was administered at a dose of 100 μg/kg, and the same dose was administered once a week from the start of administration. The animals were sacrificed two and five weeks after tumor-cell administration. We evaluated body weight at the time of tumor-cell administration and sacrifice, and after sacrifice, the weight of the affected thigh, tumor volume, and bone destruction rate were determined using micro-computed tomography. Tumor necrosis and tumor growth were measured using histological immunostaining.</p><p><strong>Results: </strong>Five weeks after tumor-cell administration, bone destruction rate was significantly lower in all groups compared to the control group (<i>p</i><0.05). Additionally, the -1w group exhibited a significantly lower bone destruction rate than 1w and 2w groups (<i>p</i><0.05). There were no significant differences in tumor necrosis, but tumor growth was significantly lower in the -1w and 0w groups (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The earlier ZA was administered, the more strongly it suppressed bone destruction and tumor cell proliferation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1984-1991"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Cardiovascular Changes Following Cerebral Ischemia in a Non-human Primate Thromboembolic Stroke Model.","authors":"Tetsuya Yoshikawa, Yuki Akiyoshi, Tsuyoshi Uchino, Hiroaki Kawaguchi","doi":"10.21873/invivo.13996","DOIUrl":"10.21873/invivo.13996","url":null,"abstract":"<p><strong>Background/aim: </strong>Acute cardiovascular changes following cerebral ischemia are significant contributors to stroke-related mortality, yet their mechanisms remain poorly understood. This study investigated cardiovascular responses in a cynomolgus monkey thromboembolic stroke model.</p><p><strong>Materials and methods: </strong>A thromboembolic stroke model was induced in eight male animals (aged 4 to 6 years) by occlusion of the left middle cerebral artery with an autologous blood clod. Arterial blood pressure, heart rate, respiratory rate, and body temperature were continuously monitored in conscious, free-moving animals for 24 h post-embolization using a telemetry system.</p><p><strong>Results: </strong>Blood pressure, heart rate, and respiratory rate significantly increased following embolization and these increases persisted for 24 h. Circadian rhythm disruption was suggested by elevated nighttime respiratory rate and body temperature. Three moribund animals exhibited higher blood pressure, heart rate, and respiratory rate compared to five non-moribund animals, along with a drop in body temperature in the hours before death. Electrocardiographic analysis revealed no major abnormalities in non-moribund animals, but the moribund animals showed arrhythmias and ST-segment elevation before death.</p><p><strong>Conclusion: </strong>These cardiovascular changes closely resemble those observed in stroke-heart syndrome in humans, highlighting the relevance of this non-human primate model in studying acute cardiovascular complications following cerebral ischemia. This model could be applied in the development of therapies for managing post-stroke cardiovascular events.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1992-2003"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation.","authors":"Ting-Hao Tu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.14014","DOIUrl":"10.21873/invivo.14014","url":null,"abstract":"<p><strong>Background/aim: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease with systemic manifestations. Methotrexate (MTX) remains a cornerstone of RA treatment, offering significant therapeutic benefits; however, it is also associated with adverse effects, particularly myelosuppression. Molecular hydrogen, recognized for its anti-inflammatory and antioxidant properties, has demonstrated potential in mitigating oxidative stress and modulating immune responses in RA. This study aimed to evaluate the efficacy of molecular hydrogen therapy in alleviating MTX-induced myelosuppression while preserving its immunoregulatory effects in a patient with RA.</p><p><strong>Case report: </strong>We present the case of a 66-year-old Taiwanese female diagnosed with RA according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria. The patient presented to the emergency department on August 30, 2024, with oral ulcers, sore throat, weakness, and diarrhea. Clinical assessment revealed hypotension, tachycardia, pancytopenia, hepatic insufficiency, and acute kidney injury. Outpatient medications were discontinued, and molecular hydrogen therapy was initiated. The patient exhibited marked clinical improvement, with normalization of laboratory parameters. Flow cytometry analysis demonstrated a progressive increase in the percentages of PD-1+ subsets of Th and Tc cells, as well as memory and activated regulatory T (Treg) cells. In contrast, B regulatory (Breg) cell levels remained unchanged. No adverse events were observed during the course of hydrogen therapy.</p><p><strong>Conclusion: </strong>This is the first case report to highlight severe MTX-induced myelosuppression in an RA patient and to demonstrate the potential of molecular hydrogen therapy in modulating immune markers.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2186-2195"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Older Patients Undergoing Surgery for Esophageal Squamous Cell Carcinoma.","authors":"Takuya Iguchi, Satoshi Nakamura, Masato Kitazawa, Yuta Yamamoto, Satoru Miyazaki, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Ryosuke Aoki, Park Yonghan, Yuji Soejima","doi":"10.21873/invivo.14024","DOIUrl":"10.21873/invivo.14024","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal cancer is a leading cause of death among males worldwide, including Japan, where squamous cell carcinoma is the most common type. Treatment decisions can be complicated, especially for older patients undergoing esophagectomy, which, while effective, is invasive and incurs significant risks.</p><p><strong>Patients and methods: </strong>A retrospective review of 126 consecutive patients with esophageal squamous cell carcinoma (ESCC) who underwent open or thoracoscopic esophagectomy between January 2010 and April 2023 was conducted. Older patients aged ≥75 years (n=24) were compared with non-older patients aged <75 years (n=102).</p><p><strong>Results: </strong>Both estimated Glomerular Filtration Rate (eGFR) and albumin levels were notably lower in older patients with a more extensive medical history and higher American Society of Anesthesiologists Physical Status scores. However, there were no differences in sex, Body Mass Index, or pathological stage. Both groups showed similar characteristics in terms of the esophagectomy approach, field dissection, preoperative treatment, operation duration, bleeding, postoperative complications, and hospital stay. No differences were observed between non-older and older groups regarding overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS) (5-year OS: 63.4% <i>vs</i>. 29.2%, respectively, <i>p</i>=0.119; 5-year RFS: 48.6% <i>vs</i>. 33.9%, respectively, <i>p</i>=0.612; 5-year DSS: 73.2% and 46.2%, respectively, <i>p</i>=0.978). Additionally, multivariate survival analysis indicated that pathological N stage [hazard ratio (HR)=2.13; 95% confidence interval (CI)=1.10-4.12; <i>p</i>=0.025] and pathological T stage (HR=2.16; 95%CI=1.13-4.15; <i>p</i>=0.021) were independent prognostic factors for OS. However, age was not a prognostic factor.</p><p><strong>Conclusion: </strong>Esophagectomy for patients aged 75 years or older provides comparable long-term outcomes without increasing postoperative complications compared with patients younger than 75 years.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2286-2294"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian Cancer and the Risk of Cataract Episodes: A Nationwide Cohort Study.","authors":"Chia-Yi Lee, Shun-Fa Yang, Elsa Lin-Chin Mai, Yu-Ling Chang, Jing-Yang Huang, Chao-Kai Chang","doi":"10.21873/invivo.14026","DOIUrl":"10.21873/invivo.14026","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of this study was to explore the potential association between ovarian cancer and cataracts using the Longitudinal Health Insurance Research Database (LHIRD) of Taiwan.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted, and patients with ovarian cancer were age-matched with non-ovarian cancer patients in a 1:4 ratio. A total of 4,980 and 19,920 participants were classified into the ovarian cancer and non-ovarian cancer groups, respectively. The primary outcome was the presence of cataracts and cataract surgery. Cox proportional hazard regression was used to calculate the adjusted hazard ratio (aHR) and the 95% confidence intervals (CIs) of the primary outcomes between the groups.</p><p><strong>Results: </strong>A total of 484 and cataract events were recorded in the ovarian cancer group, while 2,383 cataract events were recorded in the non-ovarian cancer group. The ovarian cancer group had a non-significantly higher incidence of cataracts compared to the non-ovarian cancer group (aHR=1.07, 95%CI=0.97-1.19, <i>p</i>=0.074), and the incidences of individuals with advanced cataracts receiving surgery were statistically equal between the ovarian cancer group and the non-ovarian cancer group (aHR=0.93, 95%CI=0.79-1.10, <i>p</i>=0.397). In subgroup analyses, differences in cataract incidences were not significant between ovarian cancer and non-ovarian cancer subgroups with different ages or durations of ovarian cancer (all <i>p</i>>0.05).</p><p><strong>Conclusion: </strong>Ovarian cancer is associated with a marginally higher incidence of cataracts and cataract surgery.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2302-2310"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir.","authors":"Yuta Nakamaru, Ken-Ichi Sako, Naohito Ide, Yoshikazu Matsuda, Fumiyoshi Yamashita, Tomoji Maeda","doi":"10.21873/invivo.14005","DOIUrl":"10.21873/invivo.14005","url":null,"abstract":"<p><strong>Background/aim: </strong>Lopinavir (LPV) combined with ritonavir (LPV/r) was initially developed to treat human immunodeficiency virus (HIV) infection and was subsequently repurposed to treat coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic. As the efficacy of LPV/r in COVID-19 treatment has not been confirmed in clinical trials, LPV/r is not included in the Japanese COVID-19 treatment guidelines. Furthermore, previous clinical studies have not demonstrated the benefit of LPV/r against COVID-19 when used at the same dose as that used to treat HIV infection. Therefore, the aim of this study was to determine the optimal LPV/r dose combination for COVID-19 treatment.</p><p><strong>Patients and methods: </strong>Based on data from healthy volunteers and patients with HIV infection, maximum-effect models were used to estimate the relationship between LPV clearance and ritonavir plasma concentration. Pharmacokinetic simulations were performed using a range of assumptions based on previously reported modeling equations.</p><p><strong>Results: </strong>The standard LPV/r dose combination of 400 mg/100 mg twice daily did not yield optimal blood concentrations. Based on the pharmacokinetic booster effect of ritonavir, the estimated optimal dose combination was 400 mg LPV boosted with 1,200 mg ritonavir.</p><p><strong>Conclusion: </strong>These findings provide a basis to quantify the booster effect of ritonavir on LPV in COVID-19 treatment and calculate the optimal LPV and ritonavir dose combination.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2101-2108"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Emergent Endoscopic Evaluation for Corrosive Injuries: Should We Do It or Not?","authors":"Ji Hyun Kim, Ji Min Kim, Bumhee Park, Jong Sun Park, Jong Hoon Park, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Gil Ho Lee, Choong-Kyun Noh","doi":"10.21873/invivo.14048","DOIUrl":"10.21873/invivo.14048","url":null,"abstract":"<p><strong>Background/aim: </strong>Although emergency endoscopic evaluation of patients presenting with corrosive ingestion may facilitate prognosis prediction, the role of early endoscopic evaluation remains unclear. Therefore, we aimed to select patients who required emergency endoscopic evaluation based on the initial admission information and to investigate the factors associated with Zargar grade ≥2b in patients with corrosive ingestion.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed patients with corrosive ingestion who visited the emergency department between 2010 and 2023. We investigated short- and long-term endoscopic outcomes after corrosive ingestion. Using logistic regression analysis, we investigated the factors associated with endoscopic mucosal damage of Zargar grade ≥2b.</p><p><strong>Results: </strong>A total of 211 patients were enrolled. The most common reason for and type of corrosive ingestion were suicidal intent (n=138, 65.4%) and alkaline substrates (n=181, 85.5%), respectively. The median (interquartile range, IQR) of endoscopy time after admission was 455 min (235-890 min), and 92.9% (n=196) of patients underwent endoscopic evaluation within 48 h. At the initial endoscopic evaluation, 47.9% (n=101) of the patients had no mucosal injury. Stricture was observed in 2.4% (n=5) during the follow-up period, and three (1.4%) deaths occurred. In multivariate logistic analysis, bleeding events [odds ratio (OR)=12.2, 95% confidence interval (CI)=1.619-164.581, <i>p</i>=0.024] and leukocytosis (OR=2.9, 95%CI=1.138-7.331, <i>p</i>=0.023) were significant risk factors for Zargar grade ≥2b. However, the amount ingested was not revealed to be a risk factor for Zargar grade ≥2b.</p><p><strong>Conclusion: </strong>Mucosal injury was mild in most patients admitted to the emergency department after corrosive ingestion, regardless of the amount ingested.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2474-2484"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation Between Aortic Stenosis and the Subsequent Incidence of Optic Neuropathy: A Population-based Cohort Study.","authors":"Chia-Yi Lee, Shun-Fa Yang, Elsa Lin-Chin Mai, Jing-Yang Huang, Chao-Bin Yeh, Chao-Kai Chang","doi":"10.21873/invivo.14009","DOIUrl":"10.21873/invivo.14009","url":null,"abstract":"<p><strong>Background/aim: </strong>To survey the potential correlation between aortic stenosis (AS) and subsequent optic neuropathies of glaucoma and ischemic optic neuropathy.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted with the use of the TriNetX database, a project by the US Collaborative Network which enrolled 68 healthcare institutions. PSM There were 426,980 and 426,980 people divided into the AS and non-AS groups after exclusion. The primary outcomes were the development of glaucoma and ischemic optic neuropathy. Cox proportional hazard regression was used to produce the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of the optic neuropathies between groups.</p><p><strong>Results: </strong>There were 11,717 and 8,676 glaucoma episodes found in the AS and no-AS groups, and there were 566 and 391 ischemic optic neuropathy episodes found in the AS and no-AS groups. The AS group had a significantly higher risk of glaucoma (aHR=1.277, 95% CI=1.242-1.312, <i>p</i><0.001) and ischemic optic neuropathy (aHR=1.362, 95% CI=1.197-1.549, <i>p</i><0.001) compared to the non-AS population. The cumulative probability of glaucoma and ischemic optic neuropathy were significantly higher in the AS group than the non-AS group (both <i>p</i><0.001). In the multivariate analysis, the incidence of ischemic optic neuropathy was significantly higher in the AS group compared to that of the non-AS group with different characteristics except in those with Asian race, aged 20-44 years old, and aged 65-80 years old (all 95% CIs included 1).</p><p><strong>Conclusion: </strong>The existence of AS correlates to higher risk of developing glaucoma and ischemic optic neuropathy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2133-2143"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of Interleukin-4 Promoter Genotypes to Gastric Cancer Risk in Taiwan.","authors":"Chun-Kai Fu, Hsu-Tung Lee, Ya-Chen Yang, Jaw-Chyun Chen, Mei-Due Yang, Yun-Chi Wang, Hou-Yu Shih, Chia-Wen Tsai, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/invivo.13990","DOIUrl":"10.21873/invivo.13990","url":null,"abstract":"<p><strong>Background/aim: </strong>Gastric adenocarcinoma (GACA) remains a major global health concern, particularly in Asia, due to its poor prognosis and complex etiology. The interaction between genetic factors and environmental exposures, such as smoking, alcohol consumption, and <i>Helicobacter pylori</i> (<i>HP</i>) infection, plays a crucial role in GACA risk.</p><p><strong>Materials and methods: </strong><i>Interleukin-4 (IL-4)</i> gene promoter polymorphic rs2243248 (T-1099G), rs2243250 (C-589T), and rs2070874 (C-33T) genotypes were analyzed in 161 GACA patients and 483 non-cancer control subjects from a Taiwanese population by PCR-RFLP methodology. The gene-environment interactions were evaluated by stratified analysis.</p><p><strong>Results: </strong>Genotypic analysis revealed no significant association between <i>IL-4</i> polymorphisms and GACA risk (all <i>p</i>>0.05). However, interactions between <i>IL-4</i> C-589T and C-33T genotypes with <i>HP</i> infection were observed (<i>p</i>=0.0114 and 0.0009). In addition, T-1099G and C-33T genotypes interacted with alcohol consumption (<i>p</i>=0.0346 and 0.0295). T-1099G and C-589T variant genotypes were associated with an increased risk of metastasis (<i>p</i>=0.0313 and 0.0118). Moreover, <i>IL-4</i> polymorphisms did not correlate with smoking behavior in influencing GACA susceptibility.</p><p><strong>Conclusion: </strong>While <i>IL-4</i> polymorphisms alone are not predictors of GACA risk, their interactions with environmental factors may contribute to the progression of the disease. Our study emphasizes the need for further research to explore the clinical implications of <i>IL-4</i> genetic variants in diverse populations and their role in GACA progression.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1912-1923"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}